PBA-0111

N/A

Report date: 2025/02/12 15:17:30

Base Information

Drug NamePBA-0111
Drug Alias NamePBA-0111
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTransforming growth factor beta activator LRRC32 inhibitors
TargetsTransforming growth factor beta activator LRRC32
Therapy Area/IndicationsTriple Negative Breast NeoplasmsSquamous Cell Carcinoma of Head and NeckSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPure Biologics SA
China Registration ClassN/A

Develop Information

Active CompaniesPure Biologics SA
Inactive CompaniesN/A
Active IndicationsTriple Negative Breast NeoplasmsSquamous Cell Carcinoma of Head and NeckSarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A